Skip to Content

'
Daniel D. Karp, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Medical Director, Clinical Translational Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

New drug development, combined modality therapy for regionally advanced lung cancer, medical graphics and informatics, cancer chemoprevention.

 

Since the early 1980s, I have been involved in a number of aspects of aerodigestive (head and neck & lung) cancer clinical research.  This balance over the years has shifted more to lung cancer and other malignancies of the chest.

 

In my role as Director of the MDACC Clinical and Translational Research Center (CTRC) I have the opportunity to work with a number of our faculty who are developing the newest agents for cancer.  In the CTRC we are developing new ways to use graphics and computer applications (informatics) to make individual research protocols more intuitive and easier to conduct.  We strive to help patients become more knowledgeable in research-based care.

 

Ultimately, a major part of the solution to the lung cancer problem is prevention. Dr. Waun Ki Hong is a world leader in this area and I have had the honor of a close working relationship with Dr. Hong since 1982. Currently, I am the Chair of a large National Cancer Institute (NCI) Sponsored research protocol evaluating selenium chemoprevention in patients who have had surgery for stage I lung cancer.

 

I am proud to have had a role in the early clinical trials of epirubicin, the taxanes, and the new targeted oral inhibitors of the epidermal and vascular growth factor receptors. Our recent studies of the insulin growth factor receptor (IGFr) an inhibitor figitumumab plus chemotherapy have shown promising early results.

 

We all look forward to the day when patients whose cancers cannot be prevented or cured can live with lung cancer rather than die from it.

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: Unit 432
Houston, TX 77030
Room Number: FC9.3056
Phone: 713-745-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

1973 Duke University School of Medicine, Durham, NC, MD, Medicine
1969 Harvard University, Cambridge, MA, AB

Postgraduate Training

1978-1980 Fellowship in Medical Oncology, Sidney Farber Cancer Institute, Boston, MA
1976-1978 Fellowship in Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Hanover, NH
1976-1977 Clinical Fellow, American Cancer Society, Hanover, NH
1974-1976 Resident in Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH
1973-1974 Intern in Medicine, Dartmouth Hitchcock Medical Center, Hanover, NH
1973 Postgraduate Fellow in Hematology/Oncology, Duke University School of Medicine, Durham, NC

Selected Publications

Peer-Reviewed Original Research Articles
1. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp DD, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 22(16):3238-47, 8/2004. PMID: 15310767.
2. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97(2):94-102, 1/2005. PMID: 15657339.
3. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA, Picchi MA. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11(18):6505-11, 2005. PMID: 16166426.
4. Lam P, Berman S, Thurer R, Ashiku S, DeCamp M, Goldstein M, Schumer S, Halmos B, Karp DD, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIa/IIIb non-small-cell lung cancer. Clin Lung Cancer 8(2):122-9, 2006. PMID: 17026813.
5. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2/8(8):745-50, 8/2007. e-Pub 8/2007. PMID: 17762342.
6. Karp DD. Selecting an Electronic Health Record System. Journal of Oncology Practice 3(3):172-173, 2007.
7. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1). e-Pub 12/2008. PMID: 19066370.
8. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of Phase 1 cancer clinical trials: new challenges in study requirements. Cancer, [Epub ahead of print]. e-Pub 1/2009. PMID: 19165808.
9. Srivastava G, Rana V, Wallace S, Taylor S, Debnam M, Feng L, Suki D, Karp DD, Stewart D, Oh Y. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol 4(3):333-7, 3/2009. PMID: 19190519.
10. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 27(15). e-Pub 4/2009. PMID: 19380445.
11. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers LM, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ and Gualberto A. Use of the IGF-IR inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin: a phase I safety, pharmacokinetic and pharmacodynamic study. Submitted.

Last updated: 9/2/2009